Thrivent Financial for Lutherans
JAZZ icon

Thrivent Financial for Lutherans’s Jazz Pharmaceuticals JAZZ Stock Holding History

Thrivent Financial for Lutherans’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.86M Buy
20,406
+8
+0% +$1.4K 0.01% 1028
2025
Q4 		$3.47M Sell
20,398
-258
-1% -$39.6K 0.01% 1110
2025
Q3 		$2.72M Buy
20,656
+936
+5% +$112K 0.01% 1153
2025
Q2 		$2.09M Buy
19,720
+5,440
+38% +$591K ﹤0.01% 1330
2025
Q1 		$1.77M Sell
14,280
-56
-0.4% -$7.3K ﹤0.01% 1362
2024
Q4 		$1.76M Sell
14,336
-283
-2% -$33.4K ﹤0.01% 1523
2024
Q3 		$1.63M Sell
14,619
-11,574
-44% -$1.27M ﹤0.01% 1594
2024
Q2 		$2.8M Sell
26,193
-15,429
-37% -$1.7M 0.01% 1171
2024
Q1 		$5.01M Sell
41,622
-322
-0.8% -$39.4K 0.01% 893
2023
Q4 		$5.16M Sell
41,944
-1,782
-4% -$222K 0.01% 840
2023
Q3 		$5.66M Sell
43,726
-3,661
-8% -$488K 0.01% 767
2023
Q2 		$5.88M Sell
47,387
-515
-1% -$69.3K 0.01% 797
2023
Q1 		$7.01M Sell
47,902
-712
-1% -$105K 0.02% 699
2022
Q4 		$7.75M Sell
48,614
-36,676
-43% -$5.38M 0.02% 672
2022
Q3 		$11.4M Buy
85,290
+68,513
+408% +$10.4M 0.03% 554
2022
Q2 		$2.62M Buy
16,777
+287
+2% +$44.2K 0.01% 1085
2022
Q1 		$2.57M Buy
16,490
+206
+1% +$29.9K 0.01% 1180
2021
Q4 		$2.08M Buy
16,284
+237
+1% +$31.1K ﹤0.01% 1367
2021
Q3 		$2.09M Buy
16,047
+43
+0.3% +$6.5K ﹤0.01% 1322
2021
Q2 		$2.84M Buy
16,004
+992
+7% +$172K 0.01% 1198
2021
Q1 		$2.47M Sell
15,012
-792,382
-98% -$130M 0.01% 1283
2020
Q4 		$133M Sell
807,394
-1,331
-0.2% -$198K 0.31% 61
2020
Q3 		$115M Buy
808,725
+306,546
+61% +$38M 0.31% 68
2020
Q2 		$55.4M Buy
502,179
+936
+0.2% +$104K 0.17% 149
2020
Q1 		$50M Sell
501,243
-74,826
-13% -$9.67M 0.18% 141
2019
Q4 		$86M Buy
576,069
+28,106
+5% +$3.82M 0.24% 100
2019
Q3 		$70.2M Sell
547,963
-12,337
-2% -$1.65M 0.22% 122
2019
Q2 		$79.9M Buy
560,300
+13,500
+2% +$1.81M 0.24% 99
2019
Q1 		$78.2M Buy
546,800
+431,150
+373% +$56.2M 0.25% 97
2018
Q4 		$14.3M Buy
115,650
+10,990
+11% +$1.63M 0.05% 367
2018
Q3 		$17.6M Buy
104,660
+1,680
+2% +$289K 0.06% 358
2018
Q2 		$17.7M Buy
102,980
+83,640
+432% +$13.7M 0.06% 349
2018
Q1 		$2.92M Buy
+19,340
New +$2.84M 0.01% 780
2014
Q2 		– Sell
-36,600
Closed -$5.08M – 1725
2014
Q1 		$5.08M Buy
+36,600
New +$5.51M 0.03% 441

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Thrivent Financial for Lutherans's JAZZ Position: Q1 2026 in Review

Thrivent Financial for Lutherans increased its Jazz Pharmaceuticals (JAZZ) stake by 0.04% in Q1 2026, buying an estimated $1.4K and bringing the position to 20,406 shares worth $3.86M. The position accounts for 0.01% of the portfolio, ranked #1028.

Thrivent Financial for Lutherans first reported a position in JAZZ in Q1 2014 and has held it in 34 quarters since. The position peaked at $133M in Q4 2020. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Thrivent Financial for Lutherans held 20,406 shares of Jazz Pharmaceuticals worth $3.86M as of Q1 2026.
  • Thrivent Financial for Lutherans bought 8 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.4K.
  • Jazz Pharmaceuticals made up 0.01% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #1028 holding.
  • Thrivent Financial for Lutherans first reported a position in Jazz Pharmaceuticals in Q1 2014 and has held it in 34 quarters since.
  • Thrivent Financial for Lutherans's Jazz Pharmaceuticals position peaked at $133M in Q4 2020.
  • 571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.